BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Baxter
Teva
Dow
Chinese Patent Office
Argus Health
Healthtrust
Daiichi Sankyo
UBS
Colorcon

Generated: January 23, 2018

DrugPatentWatch Database Preview

ZURAMPIC Drug Profile

« Back to Dashboard

When do Zurampic patents expire, and when can generic versions of Zurampic launch?

Zurampic is a drug marketed by Ironwood Pharms Inc and is included in one NDA. There are seven patents protecting this drug.

This drug has one hundred and seventy-three patent family members in thirty-eight countries.

The generic ingredient in ZURAMPIC is lesinurad. Two suppliers are listed for this compound. Additional details are available on the lesinurad profile page.
Summary for ZURAMPIC
International Patents:173
US Patents:7
Applicants:1
NDAs:1
Suppliers / Packagers: 2
Bulk Api Vendors: 37
Patent Applications: 45
Drug Prices:see details
DailyMed Link:ZURAMPIC at DailyMed
Drug patent expirations by year for ZURAMPIC

US Patents and Regulatory Information for ZURAMPIC

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ironwood Pharms Inc ZURAMPIC lesinurad TABLET;ORAL 207988-001 Dec 22, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Ironwood Pharms Inc ZURAMPIC lesinurad TABLET;ORAL 207988-001 Dec 22, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Ironwood Pharms Inc ZURAMPIC lesinurad TABLET;ORAL 207988-001 Dec 22, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Ironwood Pharms Inc ZURAMPIC lesinurad TABLET;ORAL 207988-001 Dec 22, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Ironwood Pharms Inc ZURAMPIC lesinurad TABLET;ORAL 207988-001 Dec 22, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Ironwood Pharms Inc ZURAMPIC lesinurad TABLET;ORAL 207988-001 Dec 22, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Ironwood Pharms Inc ZURAMPIC lesinurad TABLET;ORAL 207988-001 Dec 22, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Ironwood Pharms Inc ZURAMPIC lesinurad TABLET;ORAL 207988-001 Dec 22, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for ZURAMPIC

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,344,012 Compounds, compositions and methods of using same for modulating uric acid levels ➤ Subscribe
8,193,234 Compounds, compositions and methods of using same for modulating uric acid levels ➤ Subscribe
7,435,752 N[S(4-aryl-triazol-3-yl).alpha.-mercaptoacetyl]-p-amino benozioc acids as HIV reverse transcriptase inhibitors ➤ Subscribe
8,552,043 N[S(4-aryl-triazol-3-yl).alpha.-mercaptoacetyl]-p-amino benzoic acids as HIV reverse transcriptase inhibitors ➤ Subscribe
8,252,828 S-triazolyl .alpha.-mercapto acetanilides as inhibitors of HIV reverse transcriptase ➤ Subscribe
8,173,690 Compounds, compositions and methods of using same for modulating uric acid levels ➤ Subscribe
8,633,232 Compounds, compositions and methods of using same for modulating uric acid levels ➤ Subscribe
8,481,581 S-triazolyl .alpha.-mercaptoacetanilides as inhibitors of HIV reverse transcriptase ➤ Subscribe
7,683,087 N[S(4-aryl-triazol-3-yl).alpha.-mercaptoacetyl] -p-amino benzoic acids as HIV reverse transcriptase inhibitors ➤ Subscribe
7,947,721 S-triazolyl .alpha.-mercaptoacetanilides as inhibitors of HIV reverse transcriptase ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for ZURAMPIC

Supplementary Protection Certificates for ZURAMPIC

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2016 00034 Denmark ➤ Subscribe PRODUCT NAME: LESINURAD ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU1/15/1080 20160222
2016024 Lithuania ➤ Subscribe PRODUCT NAME: LESINURADAS; REGISTRATION NO/DATE: EU/1/15/1080 20160218
C0031 France ➤ Subscribe PRODUCT NAME: LESINURAD; REGISTRATION NO/DATE: EU/1/15/1080 20160222
2016000060 Germany ➤ Subscribe PRODUCT NAME: LESINURAD ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/1080 20160218
2016 00034 Denmark ➤ Subscribe PRODUCT NAME: LESINURAD ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU1/15/1080 20160222
0160027 00203 Estonia ➤ Subscribe PRODUCT NAME: LESINURAAD;REG NO/DATE: EU/1/15/1080 22.02.2016
/2016 Austria ➤ Subscribe PRODUCT NAME: LESINURAD ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/1080 (MITTEILUNG) 20160222
0825 Netherlands ➤ Subscribe PRODUCT NAME: LESINURAD; REGISTRATION NO/DATE: EU/1/15/1080 20160222
90033-4 Sweden ➤ Subscribe PRODUCT NAME: LESINURAD, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; REG. NO/DATE: EU/1/15/1080 20160222
169 Luxembourg ➤ Subscribe PRODUCT NAME: LESINURAD , OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; FIRST REGISTRATION DATE: 20160222
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Healthtrust
Cantor Fitzgerald
Chinese Patent Office
Citi
Merck
Julphar
US Army
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot